Quantitative Investment Management LLC Has $10.54 Million Holdings in Eli Lilly and Co (LLY)
Quantitative Investment Management LLC raised its position in shares of Eli Lilly and Co (NYSE:LLY) by 1.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 124,800 shares of the company’s stock after buying an additional 1,200 shares during the period. Quantitative Investment Management LLC’s holdings in Eli Lilly and were worth $10,540,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Pathstone Family Office LLC lifted its position in shares of Eli Lilly and by 100.0% in the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after purchasing an additional 29 shares during the period. Gradient Investments LLC purchased a new stake in shares of Eli Lilly and in the 4th quarter worth about $103,000. Acrospire Investment Management LLC lifted its position in shares of Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the period. MPS Loria Financial Planners LLC purchased a new stake in shares of Eli Lilly and in the 2nd quarter worth about $128,000. Finally, San Francisco Sentry Investment Group CA purchased a new stake in shares of Eli Lilly and in the 2nd quarter worth about $129,000. 76.79% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts have recently commented on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, December 5th. Credit Suisse Group reaffirmed a “hold” rating and issued a $80.00 target price on shares of Eli Lilly and in a research report on Friday, February 2nd. TheStreet cut shares of Eli Lilly and from a “b” rating to a “c” rating in a research report on Monday, March 5th. Argus raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and raised their target price for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Finally, Jefferies Group set a $93.00 target price on shares of Eli Lilly and and gave the stock a “buy” rating in a research report on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $93.47.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The business had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. Eli Lilly and’s revenue was up 7.0% compared to the same quarter last year. During the same period last year, the business earned $0.95 EPS. equities research analysts predict that Eli Lilly and Co will post 4.87 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 9th. Shareholders of record on Thursday, February 15th were paid a dividend of $0.5625 per share. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a yield of 2.83%. The ex-dividend date was Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is currently -1,124.94%.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the sale, the insider now directly owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.12, for a total transaction of $780,780.00. Following the sale, the senior vice president now owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 224,761 shares of company stock valued at $19,708,235. 0.20% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/03/11/quantitative-investment-management-llc-has-10-54-million-holdings-in-eli-lilly-and-co-lly.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.